Loading…
← CockpitCompetitor Analysis › BONEX.ST Bonesupport Holding ABOpen in the cockpit ↗

Bonesupport Holding ABBONEX.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Specialties

Swedish maker of injectable bone-graft substitutes used in orthopedic and trauma surgery to help bone heal.

≈ A niche orthobiologics maker like a smaller BioventusMomentum leader 97
Mkt cap
$2.06B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$14.8M
20-day average traded
Fwd P/E
61.5×
forward earnings
ROIC−WACC
+52.4 pp
WACC 5.0%
Hurdle
-33 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · SEKSEK 318.60
1D+1.6%
1W-0.6%
1M+25.4%
3M+45.8%
6M+21.1%
YTD+69.5%
1Y+53.6%
ATR %3.6%
52w lowhigh6.3% off high

What Bonesupport does

Swedish maker of injectable bone-graft substitutes used in orthopedic and trauma surgery to help bone heal.

Is paid per use, as hospitals buy the product for each operation, so revenue follows surgery volume and whether hospitals and insurers will pay for it. The US is the main growth market.

In one line: A niche orthobiologics maker like a smaller Bioventus.

Products and services

  • CERAMENT injectable bone substitute
  • Antibiotic-eluting bone graft products

Customers

  • Orthopedic and trauma surgeons
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Orthobiologics (bone-graft substitute)…

What could go right

  • US market penetration and reimbursement wins
  • Orthopedic surgery volume growth

What could go wrong

  • Regulatory/reimbursement approval risk
  • Competition from larger orthopedics players

Moat: narrow (IP / patents, regulatory licence). Patented injectable bone-graft technology with regulatory approvals in a growing but competitive orthobiologics niche.

Headquarters: Lund, Sweden · Founded: 2005

Named competitors

Bonesupport at a glance

Size Bonesupport (BONEX.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $2.06B, the 80th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 318.60 on 18 Nov 2026.

Performance Over six months the shares gained 21.1%, against +3.1% for the median peer and +2.8% for the Sweden market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 25.2% over the last twelve months (peer median +7.9%); the operating margin is 25.4% (peer median 15.9%).

Valuation It trades at 61.5× forward earnings against a peer median of 23.7× (3rd most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -33 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 52.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026BONEX.ST 135Peer median 104
Six months, rebased to 100: Bonesupport against the median of its 20 peers (local-currency closes).

Bonesupport financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 1.40BSEK 1.17BSEK 899MSEK 591MSEK 329M
Revenue growth—+31%+52%+80%—
Gross profitSEK 1.29BSEK 1.08BSEK 824MSEK 533MSEK 290M
EBITDASEK 367MSEK 288MSEK 158MSEK 32.3M-SEK 57.8M
Net incomeSEK 272MSEK 142MSEK 134MSEK 245M-SEK 68.2M
Free cash flowSEK 331MSEK 219MSEK 64.2M-SEK 19.1M-SEK 48.9M
Capital expenditureSEK 5.20MSEK 5.20MSEK 5.84MSEK 6.06MSEK 3.28M
Total debtSEK 10.6MSEK 11.7MSEK 14.6MSEK 17.5MSEK 17.5M

Quarterly statements and history in the cockpit →

Bonesupport competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%VCYTESTA6951DRW8METN2276MEDSKAN268A6960EKTA-B300529POLYMEDCHEMMNEOGBONEX.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Bonesupport is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×50×100×150×VCYT6951DRW8METN2276MEDSKAN69606880291066EKTA-B300529POLYMED7716CHEMMNEOGBONEX.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bonesupport is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%VCYT6951DRW82276SKAN268A69606880291066EKTA-B3005297716002901BONEX.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bonesupport is the large dot.

Bonesupport competitors and peer comparison

Head to head with its named competitors (BONEX.ST vs BVS vs SYK vs MDT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bonesupport BONEX.ST$2.06B+21%+25%25%61.5×12.6%
Bioventus BVS$895M-3%+4%10%13.0×7.5%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Medtronic MDT$129B+30%+10%20%16.8×9.1%

How Bonesupport compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bonesupport against its 20 peers (data as of 18 Nov 2026)
MeasureBONEX.STPeer medianRank in peer set
1-month return+25.4%-0.6%4th highest of 21
6-month return+21.1%+3.1%6th highest of 20
Distance from 52-week high-6.3%-14.9%5th highest of 21
Revenue growth (TTM)+25.2%+7.9%4th highest of 21
Operating margin25.4%15.9%5th highest of 21
Forward P/E61.5×23.7×3rd most expensive of 19
Growth the price implies (Req g, 7 yrs)12.6%9.2%6th most demanding of 15
Growth delivered (Del g)+45.4%+11.1%highest of 15
Hurdle (Req g minus delivered)-32.8 pp-1.7 ppleast demanding of 15
ROIC minus cost of capital+52.4 pp+0.6 pphighest of 21
EV / EBITDA55.8×16.1×2nd most expensive of 16
Net debt / EBITDA-1.4×-0.8×5th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%

Questions

Who are Bonesupport's main competitors?
Named competitors: Bioventus (BVS), Stryker (SYK), Medtronic (MDT). The cockpit's measured peer set (industry) also includes Veracyte (VCYT), Establishment Labs (ESTA), JEOL (6951.T), Draegerwerk AG & Co. KGaA (DRW8.DE), Metall Zug (METN.SW), Shanghai Conant Optical (2276.HK).
Is Bonesupport expensive compared with its peers?
On forward p/e it trades at 61.5× against a peer median of 23.7×, 3rd most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -33 pp: the price already allows for a slowdown.
How has Bonesupport stock performed?
Over six months to 18 Nov 2026 the shares returned +21.1% against +3.1% for the median peer; over one year +53.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.